三生国健(688336.SH)：2025年度预计净利润29.00亿元左右 同比涨幅约311.35%

Core Viewpoint - Sanofi Guojian (688336.SH) is expected to see significant growth in revenue and net profit for the fiscal year 2025, driven by a key collaboration with Pfizer and substantial income from licensing agreements [1] Financial Projections - The company anticipates achieving approximately 4.2 billion yuan in operating revenue for 2025, an increase of about 3.006 billion yuan compared to the previous year, representing a growth rate of approximately 251.76% [1] - The projected net profit attributable to the parent company for 2025 is around 2.9 billion yuan, which is an increase of about 2.195 billion yuan year-on-year, reflecting a growth rate of approximately 311.35% [1] - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is estimated at about 2.8 billion yuan, with an increase of approximately 2.554 billion yuan compared to the previous year, indicating a staggering growth rate of about 1,038.21% [1] Strategic Partnerships - The company has established a significant collaboration with Pfizer, which has resulted in the receipt of an upfront payment for the 707 project, contributing approximately 2.89 billion yuan to the recognized revenue [1]